title: [Budget impact of growth hormone treatment during the transition phase between childhood and adulthood].
abstract: OBJECTIVE
  To estimate the budget impact of somatrophin (Genotonorm) use in growth hormone deficiency (GHD) patients during the transition between childhood and adulthood.
  
  
  METHODS
  A budget impact model was designed under the Spanish National Health System with a 5-year time horizon. Calculations of susceptible patients were based on disease prevalence (0.02%) applied to Spanish population. From total GHD cases, 60% was considered persistent and treatment candidates. An expert panel assumed that 20% of candidates would reject the treatment and 8% would withdraw therapy annually. Considered costs included: therapy costs, diagnosis (test and medical visit) and follow-up cost.
  
  
  RESULTS
  There would be 49, 93, 132, 186 and 199 patients undergoing treatment each year (2010-2014). The total impact of Genotonorm use during the transition phase would be €367,691, €655,430, €1044,874, €1334,059, and €1594,670 for years 1 to 5. The average annual cost per patient would be €7506, €7059, €7903, €7960, €7995.
  
  
  CONCLUSIONS
  GHD treatment during the transition phase in Spain poses an annual average layout of €7684/patient.
authors.affiliation: Servicio de Pediatría, Hospital del Henares, Madrid, España.
authors.forename: M A
authors.initials: MA
authors.lastname: Donoso Sanz
authors.forename: S
authors.initials: S
authors.lastname: Díaz Cerezo
authors.forename: I
authors.initials: I
authors.lastname: Oyagüez Martín
authors.forename: M A
authors.initials: MA
authors.lastname: Casado Gómez
mesh_terms: D000293:Adolescent; D000465:Algorithms; D002017:Budgets; D002648:Child; D003940:Diagnostic Techniques, Endocrine / Q000191:economics; D016527:Drug Costs; D016903:Drug Monitoring / Q000191:economics; D004363:Drug Utilization; D017721:Hospital Costs; D019382:Human Growth Hormone / Q000172:deficiency / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D008962:Models, Theoretical; D009313:National Health Programs / Q000191:economics; D011628:Puberty, Delayed / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use; D013030:Spain / Q000453:epidemiology; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; D019382:Human Growth Hormone